My major research interest is in radiation therapy for lymphomas, genitourinary cancers—including prostate cancer, bladder cancer and seminoma—and late effects of treatment, especially second cancers. Current research activities include study of image guided precision radiotherapy. I also have a long-standing interest in cancer classification with an emphasis on staging and prognostic factors. In addition, my current interests include the application of modern information and communication technologies in cancer control.
Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition.
Lancet. 2015 Nov 10;
Lancet Oncol. 2015 Sep;16(10):1153-86
Lancet Oncol. 2015 Sep;16(10):1144-6
Best Pract Res Clin Obstet Gynaecol. 2015 Jun 11;
Br J Haematol. 2015 Apr 22;
Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
Pract Radiat Oncol. 2015 Apr 17;
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT.
J Clin Oncol. 2015 Mar 2;
Cancer Treat Rev. 2015 Mar;41(3):235-246
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
J Clin Oncol. 2015 Feb 17;
Clin Oncol (R Coll Radiol). 2015 Feb;27(2):67-9
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Professor, Department of Radiation Oncology, University of Toronto
President, Union for International Cancer Control (UICC)